These are in-vitro and preclinical research observations only and are not established effects in humans or animals
Aleniglipron is an oral, small-molecule drug in development for treating obesity
Updated 07/17/2020 19:40hs INSTAGRAM LIVE Q&A Selected References Cai, J., Chen, Y., Seth, S., Furukawa, S., Compans, R
Conclusion The rise of GLP1 use in adolescents with type 2 diabetes signals a powerful shift in pediatric diabetes management
For many people, the effects last several days to a week
Metabolism: Unless were seeing consistent patterns across thousands of patients. Prosecutor: Consistent patterns that arent being objectively measured or published